Barabasi, AL, Oltvai, ZN. Network biology: understanding the cell`s functional organization. Nat Rev Genet 2004, 5: 101–113.
International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004, 431: 931–945.
Hanahan, D, Weinberg, RA. The hallmarks of cancer. Cell 2000, 100: 57–70.
Greenman, C, Stephens, P, Smith, R, Dalgliesh, GL, Hunter, C, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446: 153–158.
Futreal, PA, Coin, L, Marshall, M, Down, T, Hubbard, T, et al. A census of human cancer genes. Nat Rev Cancer 2004, 4: 177–183.
Stratton, MR, Campbell, PJ, Futreal, PA. The cancer genome. Nature 2009, 458: 719–724.
Santos, E, Tronick, SR, Aaronson, SA, Pulciani, S, Barbacid, M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB‐ and Harvey‐MSV transforming genes. Nature 1982, 298: 343–347.
Parada, LF, Tabin, CJ, Shih, C, Weinberg, RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982, 297: 474–478.
Jones, PA, Baylin, SB. The epigenomics of cancer. Cell 2007, 128: 683–692.
He, L, Hannon, GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5: 522–531.
Albert, R, Jeong, H, Barabasi, AL. Error and attack tolerance of complex networks. Nature 2000, 406: 378–382.
Lane, DP, Crawford, LV. T antigen is bound to a host protein in SV40‐transformed cells. Nature 1979, 278: 261–263.
Linzer, DI, Levine, AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40‐transformed cells and uninfected embryonal carcinoma cells. Cell 1979, 17: 43–52.
Eckhart, W, Hutchinson, MA, Hunter, T. An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates. Cell 1979, 18: 925–933.
Courtneidge, SA, Smith, AE. Polyoma virus transforming protein associates with the product of the c‐src cellular gene. Nature 1983, 303: 435–439.
Whyte, P, Buchkovich, KJ, Horowitz, JM, Friend, SH, Raybuck, M, et al. Association between an oncogene and an anti‐oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 1988, 334: 124–129.
Kovesdi, I, Reichel, R, Nevins, JR. Identification of a cellular transcription factor involved in E1A trans‐activation. Cell 1986, 45: 219–228.
Whyte, P, Williamson, NM, Harlow, E. Cellular targets for transformation by the adenovirus E1A proteins. Cell 1989, 56: 67–75.
Eckner, R, Ludlow, JW, Lill, NL, Oldread, E, Arany, Z, et al. Association of p300 and CBP with simian virus 40 large T antigen. Mol Cell Biol 1996, 16: 3454–3464.
Kaplan, DR, Whitman, M, Schaffhausen, B, Pallas, DC, White, M, et al. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell 1987, 50: 1021–1029.
Hahn, WC, Weinberg, RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002, 2: 331–341.
O`Shea, CC. Viruses ‐ seeking and destroying the tumor program. Oncogene 2005, 24: 7640–7655.
O`Shea, CC. DNA tumor viruses–the spies who lyse us. Curr Opin Genet Dev 2005, 15: 18–26.
Lee, SS, Glaunsinger, B, Mantovani, F, Banks, L, Javier, RT. Multi‐PDZ domain protein MUPP1 is a cellular target for both adenovirus E4‐ORF1 and high‐risk papillomavirus type 18 E6 oncoproteins. J Virol 2000, 74: 9680–9693.
Glaunsinger, BA, Lee, SS, Thomas, M, Banks, L, Javier, R. Interactions of the PDZ‐protein MAGI‐1 with adenovirus E4‐ORF1 and high‐risk papillomavirus E6 oncoproteins. Oncogene 2000, 19: 5270–5280.
Lee, SS, Weiss, RS, Javier, RT. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997, 94: 6670–6675.
Glaunsinger, BA, Weiss, RS, Lee, SS, Javier, R. Link of the unique oncogenic properties of adenovirus type 9 E4‐ORF1 to a select interaction with the candidate tumor suppressor protein ZO‐2. EMBO J 2001, 20: 5578–5586.
Latorre, IJ, Roh, MH, Frese, KK, Weiss, RS, Margolis, B, et al. Viral oncoprotein‐induced mislocalization of select PDZ proteins disrupts tight junctions and causes polarity defects in epithelial cells. J Cell Sci 2005, 118: 4283–4293.
Hoppe, A, Beech, SJ, Dimmock, J, Leppard, KN. Interaction of the adenovirus type 5 E4 Orf3 protein with promyelocytic leukemia protein isoform II is required for ND10 disruption. J Virol 2006, 80: 3042–3049.
Yondola, MA, Hearing, P. The adenovirus E4 ORF3 protein binds and reorganizes the TRIM family member transcriptional intermediary factor 1 alpha. J Virol 2007, 81: 4264–4271.
Boyer, J, Rohleder, K, Ketner, G. Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA‐dependent protein kinase. Virology 1999, 263: 307–312.
Kleinberger, T, Shenk, T. Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A‐enhanced junB transcription. J Virol 1993, 67: 7556–7560.
Champagne, C, Landry, MC, Gingras, MC, Lavoie, JN. Activation of adenovirus type 2 early region 4 ORF4 cytoplasmic death function by direct binding to Src kinase domain. J Biol Chem 2004, 279: 25905–25915.
Gingras, MC, Champagne, C, Roy, M, Lavoie, JN. Cytoplasmic death signal triggered by SRC‐mediated phosphorylation of the adenovirus E4orf4 protein. Mol Cell Biol 2002, 22: 41–56.
Maoz, T, Koren, R, Ben‐Ari, I, Kleinberger, T. YND1 interacts with CDC55 and is a novel mediator of E4orf4‐induced toxicity. J Biol Chem 2005, 280: 41270–41277.
Estmer Nilsson, C, Petersen‐Mahrt, S, Durot, C, Shtrichman, R, Krainer, AR, et al. The adenovirus E4‐ORF4 splicing enhancer protein interacts with a subset of phosphorylated SR proteins. EMBO J 2001, 20: 864–871.
Querido, E, Marcellus, RC, Lai, A, Charbonneau, R, Teodoro, JG, et al. Regulation of p53 levels by the E1B 55‐kilodalton protein and E4orf6 in adenovirus‐infected cells. J Virol 1997, 71: 3788–3798.
Huang, MM, Hearing, P, et al. The adenovirus early region 4 open reading frame 6/7 protein regulates the DNA binding activity of the cellular transcription factor, E2F, through a direct complex. Genes Dev 1989, 3: 1699–1710.
Obert, S, O`Connor, RJ, Schmid, S, Hearing, P. The adenovirus E4‐6/7 protein transactivates the E2 promoter by inducing dimerization of a heteromeric E2F complex. Mol Cell Biol 1994, 14: 1333–1346.
Bandara, LR, Lam, EW, Sorensen, TS, Zamanian, M, Girling, R, et al. DP‐1: a cell cycle‐regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein. EMBO J 1994, 13: 3104–3114.
Hu, QJ, Bautista, C, Edwards, GM, Defeo‐Jones, D, Jones, RE, et al. Antibodies specific for the human retinoblastoma protein identify a family of related polypeptides. Mol Cell Biol 1991, 11: 5792–5799.
Mayol, X, Grana, X, Baldi, A, Sang, N, Hu, Q, et al. Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene 1993, 8: 2561–2566.
Giordano, A, Whyte, P, Harlow, E, Franza, BR Jr, Beach, D, et al. A 60 kd cdc2‐associated polypeptide complexes with the E1A proteins in adenovirus‐infected cells. Cell 1989, 58: 981–990.
Fax, P, Lipinski, KS, Esche, H, Brockmann, D. cAMP‐independent activation of the adenovirus type 12 E2 promoter correlates with the recruitment of CREB‐1/ATF‐1, E1A(12S), and CBP to the E2‐CRE. J Biol Chem 2000, 275: 8911–8920.
Liu, F, Green, MR. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell 1990, 61: 1217–1224.
Scholer, HR, Ciesiolka, T, Gruss, P. A nexus between Oct‐4 and E1A: implications for gene regulation in embryonic stem cells. Cell 1991, 66: 291–304.
Horikoshi, N, Maguire, K, Kralli, A, Maldonado, E, Reinberg, D, et al. Direct interaction between adenovirus E1A protein and the TATA box binding transcription factor IID. Proc Natl Acad Sci U S A 1991, 88: 5124–5128.
Giordano, A, Lee, JH, Scheppler, JA, Herrmann, C, Harlow, E, et al. Cell cycle regulation of histone H1 kinase activity associated with the adenoviral protein E1A. Science New York, N.Y 1991, 253: 1271–1275.
Boyd, JM, Subramanian, T, Schaeper, U, La Regina, M, Bayley, S, et al. A region in the C‐terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24‐ras mediated transformation, tumorigenesis and metastasis. EMBO J 1993, 12: 469–478.
Taylor, DA, Kraus, VB, Schwarz, JJ, Olson, EN, Kraus, WE. E1A‐mediated inhibition of myogenesis correlates with a direct physical interaction of E1A12S and basic helix‐loop‐helix proteins. Mol Cell Biol 1993, 13: 4714–4727.
Lewis, BA, Tullis, G, Seto, E, Horikoshi, N, Weinmann, R, et al. Adenovirus E1A proteins interact with the cellular YY1 transcription factor. J Virol 1995, 69: 1628–1636.
Folkers, GE, van der Saag, PT. Adenovirus E1A functions as a cofactor for retinoic acid receptor beta (RAR beta) through direct interaction with RAR beta. Mol Cell Biol 1995, 15: 5868–5878.
Somasundaram, K, Jayaraman, G, Williams, T, Moran, E, Frisch, S, et al. Repression of a matrix metalloprotease gene by E1A correlates with its ability to bind to cell type‐specific transcription factor AP‐2. Proc Natl Acad Sci U S A 1996, 93: 3088–3093.
Reid, JL, Bannister, AJ, Zegerman, P, Martinez‐Balbas, MA, Kouzarides, T. E1A directly binds and regulates the P/CAF acetyltransferase. EMBO J 1998, 17: 4469–4477.
Lipinski, KS, Esche, H, Brockmann, D. Amino acids 1–29 of the adenovirus serotypes 12 and 2 E1A proteins interact with rap30 (TF(II)F) and TBP in vitro. Virus Res 1998, 54: 99–106.
Mazzarelli, JM, Mengus, G, Davidson, I, Ricciardi, RP. The transactivation domain of adenovirus E1A interacts with the C terminus of human TAF(II)135. J Virol 1997, 71: 7978–7983.
Boyer, TG, Martin, ME, Lees, E, Ricciardi, RP, Berk, AJ. Mammalian Srb/Mediator complex is targeted by adenovirus E1A protein. Nature 1999, 399: 276–279.
Look, DC, Roswit, WT, Frick, AG, Gris‐Alevy, Y, Dickhaus, DM, et al. Direct suppression of Stat1 function during adenoviral infection. Immunity 1998, 9: 871–880.
Nishihara, A, Hanai, J, Imamura, T, Miyazono, K, Kawabata, M. E1A inhibits transforming growth factor‐beta signaling through binding to Smad proteins. J Biol Chem 1999, 274: 28716–28723.
Hateboer, G, Gennissen, A, Ramos, YF, Kerkhoven, RM, Sonntag‐Buck, V, et al. BS69, a novel adenovirus E1A‐associated protein that inhibits E1A transactivation. EMBO J 1995, 14: 3159–3169.
Turnell, AS, Grand, RJ, Gorbea, C, Zhang, X, Wang, W, et al. Regulation of the 26S proteasome by adenovirus E1A. EMBO J 2000, 19: 4759–4773.
Zhang, X, Turnell, AS, Gorbea, C, Mymryk, JS, Gallimore, PH, et al. The targeting of the proteasomal regulatory subunit S2 by adenovirus E1A causes inhibition of proteasomal activity and increased p53 expression. J Biol Chem 2004, 279: 25122–25133.
Ansieau, S, Strobl, LJ, Leutz, A. Activation of the Notch‐regulated transcription factor CBF1/RBP‐Jkappa through the 13 SE1A oncoprotein. Genes Dev 2001, 15: 380–385.
Fax, P, Carlson, CR, Collas, P, Tasken, K, Esche, H, et al. Binding of PKA‐RIIalpha to the Adenovirus E1A12S oncoprotein correlates with its nuclear translocation and an increase in PKA‐dependent promoter activity. Virology 2001, 285: 30–41.
Sang, N, Severino, A, Russo, P, Baldi, A, Giordano, A, et al. RACK1 interacts with E1A and rescues E1A‐induced yeast growth inhibition and mammalian cell apoptosis. J Biol Chem 2001, 276: 27026–27033.
Fuchs, M, Gerber, J, Drapkin, R, Sif, S, Ikura, T, et al. The p400 complex is an essential E1A transformation target. Cell 2001, 106: 297–307.
Xin, H, D`Souza, S, Fang, L, Lengyel, P, Choubey, D. p202, an interferon‐inducible negative regulator of cell growth, is a target of the adenovirus E1A protein. Oncogene 2001, 20: 6828–6839.
Lang, SE, Hearing, P. The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone acetyltransferase complex. Oncogene 2003, 22: 2836–2841.
Cha, EJ, Oh, BC, Wee, HJ, Chi, XZ, Goh, YM, et al. E1A physically interacts with RUNX3 and inhibits its transactivation activity. J Cell Biochem 2008, 105: 236–244.
Hateboer, G, Hijmans, EM, Nooij, JB, Schlenker, S, Jentsch, S, et al. mUBC9, a novel adenovirus E1A‐interacting protein that complements a yeast cell cycle defect. J Biol Chem 1996, 271: 25906–25911.
Han, J, Sabbatini, P, Perez, D, Rao, L, Modha, D, et al. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53‐inducible and death‐promoting Bax protein. Genes Dev 1996, 10: 461–477.
Farrow, SN, White, JH, Martinou, I, Raven, T, Pun, KT, et al. Cloning of a bcl‐2 homologue by interaction with adenovirus E1B 19K. Nature 1995, 374: 731–733.
Yasuda, M, Theodorakis, P, Subramanian, T, Chinnadurai, G. Adenovirus E1B‐19K/BCL‐2 interacting protein BNIP3 contains a BH3 domain and a mitochondrial targeting sequence. J Biol Chem 1998, 273: 12415–12421.
Han, J, Sabbatini, P, White, E. Induction of apoptosis by human Nbk/Bik, a BH3‐containing protein that interacts with E1B 19K. Mol Cell Biol 1996, 16: 5857–5864.
Kasof, GM, Goyal, L, White, E. Btf, a novel death‐promoting transcriptional repressor that interacts with Bcl‐2‐related proteins. Mol Cell Biol 1999, 19: 4390–4404.
Rao, L, Modha, D, White, E. The E1B 19K protein associates with lamins in vivo and its proper localization is required for inhibition of apoptosis. Oncogene 1997, 15: 1587–1597.
Kao, CC, Yew, PR, Berk, AJ. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 1990, 179: 806–814.
Punga, T, Akusjarvi, G. The adenovirus‐2 E1B‐55K protein interacts with a mSin3A/histone deacetylase 1 complex. FEBS Lett 2000, 476: 248–252.
Liu, Y, Shevchenko, A, Berk, AJ. Adenovirus exploits the cellular aggresome response to accelerate inactivation of the MRN complex. J Virol 2005, 79: 14004–14016.
Baker, A, Rohleder, KJ, Hanakahi, LA, Ketner, G. Adenovirus E4 34k and E1b 55k oncoproteins target host DNA ligase IV for proteasomal degradation. J Virol 2007, 81: 7034–7040.
Gabler, S, Schutt, H, Groitl, P, Wolf, H, Shenk, T, et al. E1B 55‐kilodalton‐associated protein: a cellular protein with RNA‐binding activity implicated in nucleocytoplasmic transport of adenovirus and cellular mRNAs. J Virol 1998, 72: 7960–7971.
Harada, JN, Shevchenko, A, Pallas, DC, Berk, AJ. Analysis of the adenovirus E1B‐55K‐anchored proteome reveals its link to ubiquitination machinery. J Virol 2002, 76: 9194–9206.
Kiyono, T, Hiraiwa, A, Fujita, M, Hayashi, Y, Akiyama, T, et al. Binding of high‐risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997, 94: 11612–11616.
Huibregtse, JM, Scheffner, M, Howley, PM. Cloning and expression of the cDNA for E6‐AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 1993, 13: 775–784.
Crook, T, Tidy, JA, Vousden, KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans‐activation. Cell 1991, 67: 547–556.
Chen, JJ, Hong, Y, Rustamzadeh, E, Baleja, JD, Androphy, EJ. Identification of an alpha helical motif sufficient for association with papillomavirus E6. J Biol Chem 1998, 273: 13537–13544.
Ronco, LV, Karpova, AY, Vidal, M, Howley, PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor‐3 and inhibits its transcriptional activity. Genes Dev 1998, 12: 2061–2072.
Tong, X, Howley, PM. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc Natl Acad Sci U S A 1997, 94: 4412–4417.
Jing, M, Bohl, J, Brimer, N, Kinter, M, Vande Pol, SB. Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins. J Virol 2007, 81: 2231–2239.
Degenhardt, YY, Silverstein, SJ. Gps2, a protein partner for human papillomavirus E6 proteins. J Virol 2001, 75: 151–160.
Degenhardt, YY, Silverstein, S. Interaction of zyxin, a focal adhesion protein, with the e6 protein from human papillomavirus type 6 results in its nuclear translocation. J Virol 2001, 75: 11791–11802.
Filippova, M, Johnson, MM, Bautista, M, Filippov, V, Fodor, N, et al. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J Virol 2007, 81: 4116–4129.
Patel, D, Huang, SM, Baglia, LA, McCance, DJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co‐activation by CBP and p300. EMBO J 1999, 18: 5061–5072.
Thomas, M, Banks, L. Inhibition of Bak‐induced apoptosis by HPV‐18 E6. Oncogene 1998, 17: 2943–2954.
Filippova, M, Parkhurst, L, Duerksen‐Hughes, PJ. The human papillomavirus 16 E6 protein binds to Fas‐associated death domain and protects cells from Fas‐triggered apoptosis. J Biol Chem 2004, 279: 25729–25744.
Filippova, M, Song, H, Connolly, JL, Dermody, TS, Duerksen‐Hughes, PJ. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF‐induced apoptosis. J Biol Chem 2002, 277: 21730–21739.
Kumar, A, Zhao, Y, Meng, G, Zeng, M, Srinivasan, S, et al. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol 2002, 22: 5801–5812.
Lu, Z, Hu, X, Li, Y, Zheng, L, Zhou, Y, et al. Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem 2004, 279: 35664–35670.
Gao, Q, Kumar, A, Singh, L, Huibregtse, JM, Beaudenon, S, et al. Human papillomavirus E6‐induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res 2002, 62: 3315–3321.
Kuhne, C, Banks, L. E3‐ubiquitin ligase/E6‐AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J Biol Chem 1998, 273: 34302–34309.
Iftner, T, Elbel, M, Schopp, B, Hiller, T, Loizou, JI, et al. Interference of papillomavirus E6 protein with single‐strand break repair by interaction with XRCC1. EMBO J 2002, 21: 4741–4748.
Nakagawa, S, Huibregtse, JM. Human scribble (Vartul) is targeted for ubiquitin‐mediated degradation by the high‐risk papillomavirus E6 proteins and the E6AP ubiquitin‐protein ligase. Mol Cell Biol 2000, 20: 8244–8253.
Gao, Q, Kumar, A, Srinivasan, S, Singh, L, Mukai, H, et al. PKN binds and phosphorylates human papillomavirus E6 oncoprotein. J Biol Chem 2000, 275: 14824–14830.
Li, S, Labrecque, S, Gauzzi, MC, Cuddihy, AR, Wong, AH, et al. The human papilloma virus (HPV)‐18 E6 oncoprotein physically associates with Tyk2 and impairs Jak‐STAT activation by interferon‐alpha. Oncogene 1999, 18: 5727–5737.
Zhang, Y, Fan, S, Meng, Q, Ma, Y, Katiyar, P, et al. BRCA1 interaction with human papillomavirus oncoproteins. J Biol Chem 2005, 280: 33165–33177.
Dyson, N, Howley, PM, Munger, K, Harlow, E. The human papilloma virus‐16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science New York, NY 1989, 243: 934–937.
Dyson, N, Guida, P, Munger, K, Harlow, E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 1992, 66: 6893–6902.
Funk, JO, Waga, S, Harry, JB, Espling, E, Stillman, B, et al. Inhibition of CDK activity and PCNA‐dependent DNA replication by p21 is blocked by interaction with the HPV‐16 E7 oncoprotein. Genes Dev 1997, 11: 2090–2100.
Thomas, M, Matlashewski, G, Pim, D, Banks, L, et al. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV‐18 E6 through ubiquitin mediated degradation. Oncogene 1996, 13: 265–273.
Tommasino, M, Adamczewski, JP, Carlotti, F, Barth, CF, Manetti, R, et al. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 1993, 8: 195–202.
Nguyen, CL, Munger, K. Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes. Virology 2008, 380: 21–25.
McLaughlin‐Drubin, ME, Huh, KW, Munger, K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J Virol 2008, 82: 8695–8705.
Brehm, A, Nielsen, SJ, Miska, EA, McCance, DJ, Reid, JL, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999, 18: 2449–2458.
Avvakumov, N, Torchia, J, Mymryk, JS. Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene 2003, 22: 3833–3841.
Bernat, A, Avvakumov, N, Mymryk, JS, Banks, L. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 2003, 22: 7871–7881.
Huh, KW, DeMasi, J, Ogawa, H, Nakatani, Y, Howley, PM, et al. Association of the human papillomavirus type 16 E7 oncoprotein with the 600‐kDa retinoblastoma protein‐associated factor, p600. Proc Natl Acad Sci U S A 2005, 102: 11492–11497.
Zwerschke, W, Mannhardt, B, Massimi, P, Nauenburg, S, Pim, D, et al. Allosteric activation of acid alpha‐glucosidase by the human papillomavirus E7 protein. J Biol Chem 2000, 275: 9534–9541.
Zwerschke, W, Mazurek, S, Massimi, P, Banks, L, Eigenbrodt, E, et al. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci U S A 1999, 96: 1291–1296.
Mannhardt, B, Weinzimer, SA, Wagner, M, Fiedler, M, Cohen, P, et al. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth‐inhibitory insulin‐like growth factor binding protein 3. Mol Cell Biol 2000, 20: 6483–6495.
Barnard, P, McMillan, NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon‐alpha. Virology 1999, 259: 305–313.
Prathapam, T, Kuhne, C, Banks, L. The HPV‐16 E7 oncoprotein binds Skip and suppresses its transcriptional activity. Oncogene 2001, 20: 7677–7685.
Park, JS, Kim, EJ, Kwon, HJ, Hwang, ES, Namkoong, SE, et al. Inactivation of interferon regulatory factor‐1 tumor suppressor protein by HPV E7 oncoprotein; implication for the E7‐mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000, 275: 6764–6769.
Wang, YW, Chang, HS, Lin, CH, Yu, WC. HPV‐18 E7 conjugates to c‐Myc and mediates its transcriptional activity. Int J Biochem Cell Biol 2007, 39: 402–412.
Massimi, P, Pim, D, Storey, A, Banks, L. HPV‐16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene 1996, 12: 2325–2330.
Berezutskaya, E, Bagchi, S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J Biol Chem 1997, 272: 30135–30140.
Schilling, B, De‐Medina, T, Syken, J, Vidal, M, Munger, K. A novel human DnaJ protein, hTid‐1, a homolog of the Drosophila tumor suppressor protein Tid56, can interact with the human papillomavirus type 16 E7 oncoprotein. Virology 1998, 247: 74–85.
Pim, D, Massimi, P, Dilworth, SM, Banks, L. Activation of the protein kinase B pathway by the HPV‐16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 2005, 24: 7830–7838.
DeCaprio, JA, Ludlow, JW, Figge, J, Shew, JY, Huang, CM, et al. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988, 54: 275–283.
Ewen, ME, Xing, YG, Lawrence, JB, Livingston, DM. Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product‐related protein. Cell 1991, 66: 1155–1164.
Hannon, GJ, Demetrick, D, Beach, D. Isolation of the Rb‐related p130 through its interaction with CDK2 and cyclins. Genes Dev 1993, 7: 2378–2391.
Adamczewski, JP, Gannon, JV, Hunt, T. Simian virus 40 large T antigen associates with cyclin A and p33cdk2. J Virol 1993, 67: 6551–6557.
Sullivan, CS, Gilbert, SP, Pipas, JM. ATP‐dependent simian virus 40 T‐antigen‐Hsc70 complex formation. J Virol 2001, 75: 1601–1610.
Ali, SH, Kasper, JS, Arai, T, DeCaprio, JA. Cul7/p185/p193 binding to simian virus 40 large T antigen has a role in cellular transformation. J Virol 2004, 78: 2749–2757.
Cotsiki, M, Lock, RL, Cheng, Y, Williams, GL, Zhao, J, et al. Simian virus 40 large T antigen targets the spindle assembly checkpoint protein Bub1. Proc Natl Acad Sci U S A 2004, 101: 947–952.
Berger, LC, Smith, DB, Davidson, I, Hwang, JJ, Fanning, E, et al. Interaction between T antigen and TEA domain of the factor TEF‐1 derepresses simian virus 40 late promoter in vitro: identification of T‐antigen domains important for transcription control. J Virol 1996, 70: 1203–1212.
Wu, X, Avni, D, Chiba, T, Yan, F, Zhao, Q, et al. SV40 T antigen interacts with Nbs1 to disrupt DNA replication control. Genes Dev 2004, 18: 1305–1316.
Welcker, M, Clurman, BE. The SV40 large T antigen contains a decoy phosphodegron that mediates its interactions with Fbw7/hCdc4. J Biol Chem 2005, 280: 7654–7658.
Pallas, DC, Shahrik, LK, Martin, BL, Jaspers, S, Miller, TB, et al. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell 1990, 60: 167–176.
Pallas, DC, Cherington, V, Morgan, W, DeAnda, J, Kaplan, D, et al. Cellular proteins that associate with the middle and small T antigens of polyomavirus. J Virol 1988, 62: 3934–3940.
Courtneidge, SA, Smith, AE. The complex of polyoma virus middle‐T antigen and pp60c‐src. EMBO J 1984, 3: 585–591.
Courtneidge, SA, Heber, A. An 81 kd protein complexed with middle T antigen and pp60c‐src: a possible phosphatidylinositol kinase. Cell 1987, 50: 1031–1037.
Tian, Y, Li, D, Dahl, J, You, J, Benjamin, T. Identification of TAZ as a binding partner of the polyomavirus T antigens. J Virol 2004, 78: 12657–12664.
Su, W, Liu, W, Schaffhausen, BS, Roberts, TM. Association of Polyomavirus middle tumor antigen with phospholipase C‐gamma 1. J Biol Chem 1995, 270: 12331–12334.
Pallas, DC, Fu, H, Haehnel, LC, Weller, W, Collier, RJ, et al. Association of polyomavirus middle tumor antigen with 14‐3‐3 proteins. Science New York, NY 1994, 265: 535–537.
Dilworth, SM, Brewster, CE, Jones, MD, Lanfrancone, L, Pelicci, G, et al. Transformation by polyoma virus middle T‐antigen involves the binding and tyrosine phosphorylation of Shc. Nature 1994, 367: 87–90.
Cheng, SH, Espino, PC, Marshall, J, Harvey, R, Merrill, J, et al. Structural elements that regulate pp59c‐fyn catalytic activity, transforming potential, and ability to associate with polyomavirus middle‐T antigen. J Virol 1991, 65: 170–179.
Kornbluth, S, Sudol, M, Hanafusa, H. Association of the polyomavirus middle‐T antigen with c‐yes protein. Nature 1987, 325: 171–173.
Li, Y, Kang, J, Horwitz, MS. Interaction of an adenovirus 14.7‐kilodalton protein inhibitor of tumor necrosis factor alpha cytolysis with a new member of the GTPase superfamily of signal transducers. J Virol 1997, 71: 1576–1582.
Li, Y, Kang, J, Horwitz, MS. Interaction of an adenovirus E3 14.7‐kilodalton protein with a novel tumor necrosis factor alpha‐inducible cellular protein containing leucine zipper domains. Mol Cell Biol 1998, 18: 1601–1610.
Li, Y, Kang, J, Friedman, J, Tarassishin, L, Ye, J, et al. Identification of a cell protein (FIP‐3) as a modulator of NF‐kappaB activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha‐induced apoptosis. Proc Natl Acad Sci U S A 1999, 96: 1042–1047.
Chen, P, Tian, J, Kovesdi, I, Bruder, JT. Interaction of the adenovirus 14.7‐kDa protein with FLICE inhibits Fas ligand‐induced apoptosis. J Biol Chem 1998, 273: 5815–5820.
Burgert, HG, Kvist, S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 1985, 41: 987–997.
Liu, H, Fu, J, Bouvier, M. Allele‐ and locus‐specific recognition of class I MHC molecules by the immunomodulatory E3‐19K protein from adenovirus. J Immunol 2007, 178: 4567–4575.
Bennett, EM, Bennink, JR, Yewdell, JW, Brodsky, FM. Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J Immunol 1999, 162: 5049–5052.
Dilworth, SM. Cell alterations induced by the large T‐antigens of SV40 and polyoma virus. Semin Cancer Biol 1990, 1: 407–414.
Moule, MG, Collins, CH, McCormick, F, Fried, M. Role for PP2A in ARF signaling to p53. Proc Natl Acad Sci U S A 2004, 101: 14063–14066.
Arroyo, JD, Hahn, WC. Involvement of PP2A in viral and cellular transformation. Oncogene 2005, 24: 7746–7755.
O`Shea, C, Klupsch, K, Choi, S, Bagus, B, Soria, C, et al. Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J 2005, 24: 1211–1221.
O`Shea, CC, Choi, S, McCormick, F, Stokoe, D. Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle 2005, 7: 883–888.
Wang, SS, Esplin, ED, Li, JL, Huang, L, Gazdar, A, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science New York, NY 1998, 282: 284–287.
Finlay, BB, McFadden, G. Anti‐immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 2006, 124: 767–782.
Dunn, GP, Koebel, CM, Schreiber, RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6: 836–848.
Rosa, F, Berissi, H, Weissenbach, J, Maroteaux, L, Fellous, M, et al. The beta2‐microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J 1983, 2: 239–243.
Horton, TM, Ranheim, TS, Aquino, L, Kusher, DI, Saha, SK, et al. Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis. J Virol 1991, 65: 2629–2639.
Tollefson, AE, Hermiston, TW, Lichtenstein, DL, Colle, CF, Tripp, RA, et al. Forced degradation of Fas inhibits apoptosis in adenovirus‐infected cells. Nature 1998, 392: 726–730.
Tollefson, AE, Toth, K, Doronin, K, Kuppuswamy, M, Doronina, OA, et al. Inhibition of TRAIL‐induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J Virol 2001, 75: 8875–8887.
Lee, SH, Shin, MS, Kim, HS, Park, WS, Kim, SY, et al. Somatic mutations of Fas (Apo‐1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar. J Invest Dermatol 2000, 114: 122–126.
Pai, SI, Wu, GS, Ozoren, N, Wu, L, Jen, J, et al. Rare loss‐of‐function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998, 58: 3513–3518.
Pasparakis, M. Regulation of tissue homeostasis by NF‐kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 2009, 9: 778–788.
Rothwarf, DM, Zandi, E, Natoli, G, Karin, M. IKK‐gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998, 395: 297–300.
Karin, M, Ben‐Neriah, Y. Phosphorylation meets ubiquitination: the control of NF‐[kappa]B activity. Annu Rev Immunol 2000, 18: 621–663.
Kalvakolanu, DV, Bandyopadhyay, SK, Harter, ML, Sen, GC. Inhibition of interferon‐inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. Proc Natl Acad Sci U S A 1991, 88: 7459–7463.
Zhang, JJ, Vinkemeier, U, Gu, W, Chakravarti, D, Horvath, CM, et al. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. Proc Natl Acad Sci U S A 1996, 93: 15092–15096.
Cattaneo, R, Miest, T, Shashkova, EV, Barry, MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008, 6: 529–540.
Borden, EC, Lindner, D, Dreicer, R, Hussein, M, Peereboom, D. Second‐generation interferons for cancer: clinical targets. Semin Cancer Biol 2000, 10: 125–144.
Halbert, DN, Cutt, JR, Shenk, T. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol 1985; 250–257.
Russell, WC. Update on adenovirus and its vectors. J Gen Virol 2000, 81: 2573–2604.
Rigaut, G, Shevchenko, A, Rutz, B, Wilm, M, Mann, M, et al. A generic protein purification method for protein complex characterization and proteome exploration. Nat Biotechnol 1999, 17: 1030–1032.
Puig, O, Caspary, F, Rigaut, G, Rutz, B, Bouveret, E, et al. The tandem affinity purification (TAP) method: a general procedure of protein complex purification. Methods 2001, 24: 218–229.
Gavin, AC, Bosche, M, Krause, R, Grandi, P, Marzioch, M, et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 2002, 415: 141–147.
Major, MB, Camp, ND, Berndt, JD, Yi, X, Goldenberg, SJ, et al. Wilms tumor suppressor WTX negatively regulates WNT/beta‐catenin signaling. Science New York, NY 2007, 316: 1043–1046.
Junttila, MR, Saarinen, S, Schmidt, T, Kast, J, Westermarck, J. Single‐step Strep‐tag purification for the isolation and identification of protein complexes from mammalian cells. Proteomics 2005, 5: 1199–1203.
Tackett, AJ, DeGrasse, JA, Sekedat, MD, Oeffinger, M, Rout, MP, et al. I‐DIRT, a general method for distinguishing between specific and nonspecific protein interactions. J Proteome Res 2005, 4: 1752–1756.
Zhu, H, Bilgin, M, Bangham, R, Hall, D, Casamayor, A, et al. Global analysis of protein activities using proteome chips. Science New York, NY 2001, 293: 2101–2105.
Stracker, TH, Carson, CT, Weitzman, MD. Adenovirus oncoproteins inactivate the Mre11‐Rad50‐NBS1 DNA repair complex. Nature 2002, 418: 348–352.
O`Shea, CC, Soria, C, Bagus, B, McCormick, F. Heat shock phenocopies E1B‐55K late functions and selectively sensitizes refractory tumor cells to ONYX‐015 oncolytic viral therapy. Cancer Cells 2005, 8: 61–74.
Ptacek, J, Devgan, G, Michaud, G, Zhu, H, Zhu, X, et al. Global analysis of protein phosphorylation in yeast. Nature 2005, 438: 679–684.
Gupta, R, Kus, B, Fladd, C, Wasmuth, J, Tonikian, R, et al. Ubiquitination screen using protein microarrays for comprehensive identification of Rsp5 substrates in yeast. Mol Syst Biol 2007, 3: 116.
Boyle, SN, Michaud, GA, Schweitzer, B, Predki, PF, Koleske, AJ. A critical role for cortactin phosphorylation by Abl‐family kinases in PDGF‐induced dorsal‐wave formation. Curr Biol 2007, 17: 445–451.
Iacovides, DC, O`Shea, CC, Oses‐Prieto, J, Burlingame, A, McCormick, F. Critical role for arginine methylation in adenovirus‐infected cells. J Virol 2007, 81: 13209–13217.
DeCaprio, JA. How the Rb tumor suppressor structure and function was revealed by the study of Adenovirus and SV40. Virology 2009, 384: 274–284.
Pelka, P, Ablack, JN, Fonseca, GJ, Yousef, AF, Mymryk, JS. Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes. J Virol 2008, 82: 7252–7263.
Lee, JO, Russo, AA, Pavletich, NP. Structure of the retinoblastoma tumour‐suppressor pocket domain bound to a peptide from HPV E7. Nature 1998, 391: 859–865.
Jones, RE, Wegrzyn, RJ, Patrick, DR, Balishin, NL, Vuocolo, GA, et al. Identification of HPV‐16 E7 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein. J Biol Chem 1990, 265: 12782–12785.
Psyrri, A, DiMaio, D. Human papillomavirus in cervical and head‐and‐neck cancer. Nat Clin Pract Oncol 2008, 5: 24–31.
Heck, DV, Yee, CL, Howley, PM, Munger, K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 1992, 89: 4442–4446.
Baneyx, F, Mujacic, M. Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol 2004, 22: 1399–1408.
Hosfield, D, Palan, J, Hilgers, M, Scheibe, D, McRee, DE, et al. A fully integrated protein crystallization platform for small‐molecule drug discovery. J Struct Biol 2003, 142: 207–217.
Hansen, CL, Skordalakes, E, Berger, JM, Quake, SR. A robust and scalable microfluidic metering method that allows protein crystal growth by free interface diffusion. Proc Natl Acad Sci U S A 2002, 99: 16531–16536.
Endo, Y, Sawasaki, T. High‐throughput, genome‐scale protein production method based on the wheat germ cell‐free expression system. Biotechnol Adv 2003, 21: 695–713.
Li, C, Schwabe, JW, Banayo, E, Evans, RM. Coexpression of nuclear receptor partners increases their solubility and biological activities. Proc Natl Acad Sci U S A 1997, 94: 2278–2283.
Held, D, Yeager, K, Novy, R. New co‐expression vectors for expanded compatibilities in E. coli. Innovations 2003, 18: 4–6.
Michnick, SW, Ear, PH, Manderson, EN, Remy, I, Stefan, E. Universal strategies in research and drug discovery based on protein‐fragment complementation assays. Nat Rev 2007, 6: 569–582.
Cho, US, Morrone, S, Sablina, AA, Arroyo, JD, Hahn, WC, et al. Structural basis of PP2A inhibition by small t antigen. PLoS Biol 2007, 5: e202.
Lilyestrom, W, Klein, MG, Zhang, R, Joachimiak, A, Chen, XS. Crystal structure of SV40 large T‐antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev 2006, 20: 2373–2382.
Riley, T, Sontag, E, Chen, P, Levine, A. Transcriptional control of human p53‐regulated genes. Nat Rev Mol Cell Biol 2008, 9: 402–412.
Joo, WS, Jeffrey, PD, Cantor, SB, Finnin, MS, Livingston, DM, et al. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev 2002, 16: 583–593.
Bykov, VJ, Issaeva, N, Shilov, A, Hultcrantz, M, Pugacheva, E, et al. Restoration of the tumor suppressor function to mutant p53 by a low‐molecular‐weight compound. Nat Med 2002, 8: 282–288.
Wang, W, El‐Deiry, WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008, 20: 90–96.
Soucek, L, Whitfield, J, Martins, CP, Finch, AJ, Murphy, DJ, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455: 679–683.
Dunker, AK, Cortese, MS, Romero, P, Iakoucheva, LM, Uversky, VN. Flexible nets: the roles of intrinsic disorder in protein interaction networks. FEBS J 2005, 272: 5129–5148.
Reeves, R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001, 277: 63–81.
Wright, PE, Dyson, HJ. Intrinsically unstructured proteins: re‐assessing the protein structure‐function paradigm. J Mol Biol 1999, 293: 321–331.
Ferreon, JC, Martinez‐Yamout, MA, Dyson, HJ, Wright, PE. Structural basis for subversion of cellular control mechanisms by the adenoviral E1A oncoprotein. Proc Natl Acad Sci U S A 2009, 106: 13260–13265.
Gu, W, Shi, XL, Roeder, RG. Synergistic activation of transcription by CBP and p53. Nature 1997, 387: 819–823.
Lill, NL, Grossman, SR, Ginsberg, D, DeCaprio, J, Livingston, DM. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997, 387: 823–827.
O`Connor, MJ, Zimmermann, H, Nielsen, S, Bernard, HU, Kouzarides, T. Characterization of an E1A‐CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300. J Virol 1999, 73: 3574–3581.
Stein, RW, Corrigan, M, Yaciuk, P, Whelan, J, Moran, E. Analysis of E1A‐mediated growth regulation functions: binding of the 300‐kilodalton cellular product correlates with E1A enhancer repression function and DNA synthesis‐inducing activity. J Virol 1990, 64: 4421–4427.
Ferrari, R, Pellegrini, M, Horwitz, GA, Xie, W, Berk, AJ, et al. Epigenetic reprogramming by adenovirus e1a. Science New York, NY 2008, 321: 1086–1088.
Batada, NN, Hurst, LD, Tyers, M. Evolutionary and physiological importance of hub proteins. PLoS Comput Biol 2006, 2: e88.
Romero, P, Obradovic, Z, Li, X, Garner, EC, Brown, CJ, et al. Sequence complexity of disordered protein. Proteins 2001, 42: 38–48.